Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 6/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001719 | 0.90 | TTBK1 (0.38) | TTBK1MAP3K14PAK4PIKFYVEFFAR4 | |
| SCHEMBL11970637 | 0.85 | MAP3K14 (0.47) | ALOX5APTTBK1MAP3K14PAK4PIKFYVE | |
| SCHEMBL12001702 | 0.85 | TTBK1 (0.39) | TTBK1MAP3K14PAK4PIKFYVEFFAR4 | |
| SCHEMBL11970918 | 0.84 | ALOX5AP (0.36) | ALOX5APTTBK1PRMT5FFAR4ROCK1 | |
| SCHEMBL12001561 | 0.83 | ROCK1 (0.36) | TTBK1MAP3K14PAK4PIKFYVEFFAR4 | |
| SCHEMBL12525143 | 0.82 | ALOX5AP (0.35) | ALOX5APTTBK1PRMT5FFAR4ROCK1 | |
| SCHEMBL12001615 | 0.79 | TTBK1 (0.40) | TTBK1MAP3K14PAK4PIKFYVETTBK2 | |
| SCHEMBL12001643 | 0.79 | HRH4 (0.38) | TTBK1MAP3K14PAK4PIKFYVEROCK1 | |
| SCHEMBL12001492 | 0.79 | TTBK1 (0.35) | TTBK1MAP3K14PAK4PIKFYVEFFAR4 | |
| SCHEMBL12525048 | 0.79 | TTBK1 (0.35) | TTBK1MAP3K14PAK4PIKFYVEFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | ALOX5AP 122/4885TTBK1 915/4885MAP3K14 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.